Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A1EWVY8
Tue, 27.04.2021
Formycon AG
Press Release // April 27, 2021
Formycon receives approval for early action for COVID-19 drug FYB207 as part of a grant from the Bavarian Ministry of Economic Affairs, Regional Development and Energy (StMWi)
- Consideration of FYB207 in the funding call "BayTherapie2020"
- Funded project includes development activities of FYB207 through to c [ … ]
Wed, 13.01.2021
Formycon AG
Press Release // January 13, 2021
Formycon's Scientific Collaboration Partners present FYB207 Results at International Keystone Symposium
Munich - Formycon (ISIN: DE000A1EWVY8/ WKN: A1EWVY) today announced that its academic partners of the Technical University of Munich, present results on Formycon's COVID-19 drug (FYB207).
The results of the pu [ … ]
Thu, 07.01.2021
Formycon AG
First Berlin Equity Research hat ein Research Update zu Formycon AG (ISIN:
DE000A1EWVY8) veröffentlicht. Analyst Simon Scholes bestätigt seine
BUY-Empfehlung und erhöht das Kursziel von EUR 43,00 auf EUR 78,00.
Zusammenfassung:
Nach Angaben des Biotechnologie-Fachverbandes BIO gab es Mitte Dezember
über 590 Medikamente zur Be [ … ]
Mon, 14.12.2020
Formycon AG
Press Release // December 14, 2020
Formycon Reports on Virtual Annual General Meeting 2020
- Shareholders approve all items on the agenda
- Ratification of the actions of the Management Board and Supervisory Board by a large majority
- Dr. Olaf Stiller, Peter Wendeln and Klaus Röhrig elected to the Supervisory Board
Munich - Formycon AG (I [ … ]
Wed, 09.12.2020
Formycon AG
Press Release // December 9, 2020
Innovative SARS-CoV-2 Blocker from Formycon Completely Prevents Infection of Cells
Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) together with its academic partners Prof. Dr. Ulrike Protzer, Chair of Virology, and Prof. Dr. Johannes Buchner, Chair of Biotechnology, Technical University of Munich, have pu [ … ]
Tue, 24.11.2020
Formycon AG
Press Release // November 24, 2020
Chief Operating Officer Dr. Stefan Glombitza appointed to Formycon AG's Management Board for another Four Years
Munich - The Supervisory Board of Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) has extended the appointment of Management Board member Dr. Stefan Glombitza as Chief Operating Officer (COO) until D [ … ]
Wed, 11.11.2020
Formycon AG
Press Release // November 11, 2020
Formycon Reports its Nine-month Figures for 2020
- Group turnover and other earnings total EUR 23.5 million
- EBITDA is EUR -2.0 million and corresponds to expectations
- Group revenues for 2020 remain forecast to be EUR 35.0 to 40.0 million
Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) has today [ … ]
Mon, 09.11.2020
Formycon AG
Press Release // November 9, 2020
Formycon and Bioeq announce Launch of Phase III Study of FYB202, a Biosimilar Candidate for Stelara(R)* (Ustekinumab)
- Vespucci study examines comparable efficacy, safety and immunogenicity of FYB202 and the reference product Stelara(R) in patients with moderate to severe psoriasis vulgaris (plaque psoriasis) [ … ]
Thu, 05.11.2020
Formycon AG
Publication of insider information in accordance with Article 17 of the Regulation (EU) No 596/2014 Ad-Hoc Announcement /// November 5, 2020
Formycon informs about the modified BLA-Submission Strategy for its Lucentis(R)* Biosimilar-Candidate FYB201
Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) and its licensing partner Bioeq AG ("Bioeq" [ … ]
Mon, 02.11.2020
Formycon AG
Press Release // November 2, 2020
Formycon Announces Virtual Annual General Meeting for December 10, 2020
Munich - Against the background of the COVID-19 pandemic, which is set to continue for the foreseeable future, the rules of conduct adopted by the Free State of Bavaria which are still in force, and the objective of avoiding health risks, th [ … ]